Patient Care Costs in Cancer Clinical Trials

Publication
Article
OncologyONCOLOGY Vol 15 No 6
Volume 15
Issue 6

Rep. Pryce is also cochair of the House Cancer Working Group. In March, she introduced the Access to Cancer Clinical Trials Act (H.R. 967), which would require health insurers to pay for the routine costs incurred by patients in

Rep. Pryce is also cochair of the House Cancer Working Group. InMarch, she introduced the Access to Cancer Clinical Trials Act(H.R. 967), which would require health insurers to pay for the routine costsincurred by patients in cancer clinical trials. This would be a further step infederal policy beyond the Clinton administration’s national coverage decisionthat went into effect in September 2000. The Pryce bill calls for coverage ofall participants in cancer clinical trials, regardless of age, including thoseconducted by nonfederal research entities—a category of trials not included inthe Clinton policy.

Recent Videos
Data from the SPOTLIGHT and GLOW trials reveal that zolbetuximab increased survival in patients with CLDN18.2-positive gastric or GEJ adenocarcinoma.
The incorporation of zolbetuximab in addition to chemotherapy has shown benefit in patients with Claudin 18.2–positive gastric cancers in clinical trials.
Michael J. Hall, MD, MS, FASCO, discusses the need to reduce barriers to care for those with Li-Fraumeni syndrome, including those who live in rural areas.
Patrick Oh, MD, highlights next steps for further research in treating patients with systemic therapy in addition to radiotherapy for early-stage NSCLC.
The ability of metformin to disrupt mitochondrial metabolism may help mitigate the risk of cancer in patients with Li-Fraumeni syndrome.
Related Content